Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Olink Proteomics Acquires Antibody Maker Agrisera

Olink Proteomics Acquires Antibody Maker Agrisera

May 12, 2020
|
staff reporter

NEW YORK — Olink Proteomics said on Tuesday that it has acquired Swedish antibody manufacturer Agrisera.

Terms of the transaction were not disclosed.

Olink offers protein biomarker discovery products and services based on its proximity extension assay technology, which uses oligonucleotide-labeled antibodies to enable multiplex protein measurement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Funds Sought for Vaccine Distribution

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

Virus Variant From Spain Now Across UK

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

Unexpected Loss

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

Science Papers on Long Human-Canine Relationship, Population History of Early East Asians, More

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.

Nov
17
Featured Webinar

Spatial Expression Analyses Elucidates Mechanisms of circRNAs in Cancer

Sponsored by
ACD

Circular RNAs (circRNAs) have recently gained substantial attention in the cancer research field where most, including the putative oncogene ciRS-7 (CDR1as), have been proposed to function as competitive endogenous RNAs (ceRNAs) by “sponging” specific microRNAs.

What's Popular?

In Proteomics & Protein Research

  1. SomaLogic Partners With FDA to Test Proteomic Tech for Evaluating Biosimilars

  2. Biodesix Prices $72M IPO

  3. COVID-19 Multiomic Immune Response Study Reveals Differences in Disease Progression, Severity

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.